# Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)

> **NCT06304064** · PHASE2 · COMPLETED · sponsor: **Capricor Inc.** · enrollment: 8 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **BIOLOGICAL:** Allogeneic Cardiosphere-Derived Cells (CAP-1002)

## Key facts

- **NCT ID:** NCT06304064
- **Lead sponsor:** Capricor Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-21
- **Primary completion:** 2019-03-06
- **Final completion:** 2019-03-06
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06304064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06304064, "Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06304064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*